Home Healthcare IT Idiopathic Pulmonary Fibrosis Market Size, Top Share, Industry Trends, Forecast 2033

Idiopathic Pulmonary Fibrosis Market Size & Outlook, 2025-2033

Idiopathic Pulmonary Fibrosis Market Size, Share & Trends Analysis Report By Drug Type (Nintedanib, Pirfenidone, Other Drug Types), By Mode of Action (Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes of Action), By End-User (Hospitals and Clinics, Pharmacies, Other end-users) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRHI55266DR
Last Updated: Jun, 2025
Pages: 110
Author: Debashree Bora
Format: PDF, Excel

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Idiopathic Pulmonary Fibrosis Market Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Nintedanib
        1. By Value
      3. Pirfenidone
        1. By Value
      4. Other Drug Types
        1. By Value
    3. By Mode of Action
      1. Introduction
        1. Mode of Action By Value
      2. Antifibrotic Agents
        1. By Value
      3. Tyrosine Kinase Inhibitors
        1. By Value
      4. Other Modes of Action
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospitals and Clinics
        1. By Value
      3. Pharmacies
        1. By Value
      4. Other end-users
        1. By Value
    1. Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Nintedanib
        1. By Value
      3. Pirfenidone
        1. By Value
      4. Other Drug Types
        1. By Value
    3. By Mode of Action
      1. Introduction
        1. Mode of Action By Value
      2. Antifibrotic Agents
        1. By Value
      3. Tyrosine Kinase Inhibitors
        1. By Value
      4. Other Modes of Action
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospitals and Clinics
        1. By Value
      3. Pharmacies
        1. By Value
      4. Other end-users
        1. By Value
    5. U.S.
      1. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Nintedanib
          1. By Value
        3. Pirfenidone
          1. By Value
        4. Other Drug Types
          1. By Value
      2. By Mode of Action
        1. Introduction
          1. Mode of Action By Value
        2. Antifibrotic Agents
          1. By Value
        3. Tyrosine Kinase Inhibitors
          1. By Value
        4. Other Modes of Action
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospitals and Clinics
          1. By Value
        3. Pharmacies
          1. By Value
        4. Other end-users
          1. By Value
    6. Canada
    1. Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Nintedanib
        1. By Value
      3. Pirfenidone
        1. By Value
      4. Other Drug Types
        1. By Value
    3. By Mode of Action
      1. Introduction
        1. Mode of Action By Value
      2. Antifibrotic Agents
        1. By Value
      3. Tyrosine Kinase Inhibitors
        1. By Value
      4. Other Modes of Action
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospitals and Clinics
        1. By Value
      3. Pharmacies
        1. By Value
      4. Other end-users
        1. By Value
    5. U.K.
      1. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Nintedanib
          1. By Value
        3. Pirfenidone
          1. By Value
        4. Other Drug Types
          1. By Value
      2. By Mode of Action
        1. Introduction
          1. Mode of Action By Value
        2. Antifibrotic Agents
          1. By Value
        3. Tyrosine Kinase Inhibitors
          1. By Value
        4. Other Modes of Action
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospitals and Clinics
          1. By Value
        3. Pharmacies
          1. By Value
        4. Other end-users
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Nintedanib
        1. By Value
      3. Pirfenidone
        1. By Value
      4. Other Drug Types
        1. By Value
    3. By Mode of Action
      1. Introduction
        1. Mode of Action By Value
      2. Antifibrotic Agents
        1. By Value
      3. Tyrosine Kinase Inhibitors
        1. By Value
      4. Other Modes of Action
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospitals and Clinics
        1. By Value
      3. Pharmacies
        1. By Value
      4. Other end-users
        1. By Value
    5. China
      1. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Nintedanib
          1. By Value
        3. Pirfenidone
          1. By Value
        4. Other Drug Types
          1. By Value
      2. By Mode of Action
        1. Introduction
          1. Mode of Action By Value
        2. Antifibrotic Agents
          1. By Value
        3. Tyrosine Kinase Inhibitors
          1. By Value
        4. Other Modes of Action
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospitals and Clinics
          1. By Value
        3. Pharmacies
          1. By Value
        4. Other end-users
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Singapore
    11. Taiwan
    12. South East Asia
    13. Rest of Asia-Pacific
    1. Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Nintedanib
        1. By Value
      3. Pirfenidone
        1. By Value
      4. Other Drug Types
        1. By Value
    3. By Mode of Action
      1. Introduction
        1. Mode of Action By Value
      2. Antifibrotic Agents
        1. By Value
      3. Tyrosine Kinase Inhibitors
        1. By Value
      4. Other Modes of Action
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospitals and Clinics
        1. By Value
      3. Pharmacies
        1. By Value
      4. Other end-users
        1. By Value
    5. UAE
      1. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Nintedanib
          1. By Value
        3. Pirfenidone
          1. By Value
        4. Other Drug Types
          1. By Value
      2. By Mode of Action
        1. Introduction
          1. Mode of Action By Value
        2. Antifibrotic Agents
          1. By Value
        3. Tyrosine Kinase Inhibitors
          1. By Value
        4. Other Modes of Action
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospitals and Clinics
          1. By Value
        3. Pharmacies
          1. By Value
        4. Other end-users
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Nintedanib
        1. By Value
      3. Pirfenidone
        1. By Value
      4. Other Drug Types
        1. By Value
    3. By Mode of Action
      1. Introduction
        1. Mode of Action By Value
      2. Antifibrotic Agents
        1. By Value
      3. Tyrosine Kinase Inhibitors
        1. By Value
      4. Other Modes of Action
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospitals and Clinics
        1. By Value
      3. Pharmacies
        1. By Value
      4. Other end-users
        1. By Value
    5. Brazil
      1. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Nintedanib
          1. By Value
        3. Pirfenidone
          1. By Value
        4. Other Drug Types
          1. By Value
      2. By Mode of Action
        1. Introduction
          1. Mode of Action By Value
        2. Antifibrotic Agents
          1. By Value
        3. Tyrosine Kinase Inhibitors
          1. By Value
        4. Other Modes of Action
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospitals and Clinics
          1. By Value
        3. Pharmacies
          1. By Value
        4. Other end-users
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Idiopathic Pulmonary Fibrosis Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Boehringer Ingelheim International GmbH
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. United Therapeutics Corporation
    3. Cipla Inc.
    4. Bristol-Myers Squibb Company
    5. Hoffmann-La Roche Ltd
    6. FibroGen Inc.
    7. Jubilant Pharma Limited (Jubliant Cadista Limited)
    8. MediciNova Inc.
    9. Merck & Co. Inc.
    10. Horizon Therapeutics Public Limited Company.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer
Get This Report

Download Free Sample

Our Clients:

LG Electronics
AMCAD Engineering
KOBE STEEL LTD.
Hindustan National Glass & Industries Limited
Voith Group
International Paper
Hansol Paper
Whirlpool Corporation
Sony
Samsung Electronics
Qualcomm
Google
Fiserv
Veto-Pharma
Nippon Becton Dickinson
Merck
Argon Medical Devices
Abbott
Ajinomoto
Denon
Doosan
Meiji Seika Kaisha Ltd
LG Chemicals
LCY chemical group
Bayer
Airrane
BASF
Toyota Industries
Nissan Motors
Neenah
Mitsubishi
Hyundai Motor Company

We are featured on:

WhatsApp
Chat with us on WhatsApp
Address:
Office 515 A, Amanora Chambers,
Amanora Park Town, Hadapsar,
Pune 411028, Maharashtra, India.
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
DMCA.com Protection Status
Secure Payments:
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.